Norgine BV - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related to gastrointestinal tract, gastric and hepatic conditions, critical and supportive care. Norgine offers drugs in the form of capsules, solutions, tablets, oral powder and medical device. The company also provides clinical supply services to organizations conducting clinical trials. It operates in the UK, France, Belgium, Germany and the Netherlands, among others. Norgine is headquartered in Amsterdam, the Netherlands.

Norgine BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Norgine BV, Medical Devices Deals, 2012 to YTD 2018 11
Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Norgine BV, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 14
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 15
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 16
Merus Labs Acquires Sintrom from Novartis 17
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 18
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 19
Partnerships 20
Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 20
Norgine Forms Joint Venture With SpePharm Holding 21
Merus Labs Enters into Agreement with Vansen Pharma 22
Licensing Agreements 23
Navidea Enters into License Agreement with Norgine for Lymphoseek 23
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 24
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 25
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 26
Valeant Pharma Enters into Licensing Agreement with Norgine 27
Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 28
Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 29
Equity Offering 30
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 30
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 32
Merus Labs Completes Partial Exercise of Underwriters Over Allotment Option for Public Offering of Shares for USD63 Million 33
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 34
Merus Labs Raises USD28.7 Million in Public Offering of Shares 35
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 36
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 37
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 38
Asset Transactions 39
Norgine Divests its MENA Operations and Product Rights to Acino 39
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 40
Norgine to Sell UK Rights for Somnite and Camcolit 41
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 42
Acquisition 44
Norgine Acquires Merus Labs International 44
Norgine BV - Key Competitors 46
Norgine BV - Key Employees 47
Norgine BV - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Joint Venture 50
Recent Developments 51
Strategy And Business Planning 51
Jan 24, 2018: Norgine Opens New Headquarters in Amsterdam, Netherlands 51
Government and Public Interest 52
Mar 27, 2018: Norgine Is Calling The NHS To Remove Constipation From The List Of Restricted Conditions In Proposed CCGs Guidance Constipation Is A Very Serious Condition 52
Product News 54
Oct 31, 2017: Norgine Launches PLENVU (NER1006) in the United Kingdom 54
Apr 21, 2018: New Data Show That High Quality Cleansing Improves Lesion Detection During Colonoscopy Compared to Adequate Cleansing 55
Other Significant Developments 56
Feb 26, 2018: Norgines Performance in 2017 and Priorities for 2018 56
Feb 16, 2017: Norgine Rejoins The UK Pharmaceutical Trade Body ABPI 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List Of Tables

List of Tables
Norgine BV, Pharmaceuticals & Healthcare, Key Facts 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Norgine BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Norgine BV, Deals By Therapy Area, 2012 to YTD 2018 10
Norgine BV, Medical Devices Deals, 2012 to YTD 2018 11
Norgine BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 14
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 15
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 16
Merus Labs Acquires Sintrom from Novartis 17
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 18
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 19
Altacor Enters Into Co-Promotion Agreement With Norgine For Clinitas Dry Eye Product 20
Norgine Forms Joint Venture With SpePharm Holding 21
Merus Labs Enters into Agreement with Vansen Pharma 22
Navidea Enters into License Agreement with Norgine for Lymphoseek 23
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 24
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 25
APR Applied Pharma Research And Labtec Enter Into Licensing Agreement With Norgine For Setofilm 26
Valeant Pharma Enters into Licensing Agreement with Norgine 27
Norgine Enters Into Licensing Agreement With Innovacell For ICEF15 28
Norgine Enters Into Licensing Agreement With Pegasus Biosolutions 29
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 30
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 32
Merus Labs Completes Partial Exercise of Underwriters Over Allotment Option for Public Offering of Shares for USD63 Million 33
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 34
Merus Labs Raises USD28.7 Million in Public Offering of Shares 35
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 36
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 37
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 38
Norgine Divests its MENA Operations and Product Rights to Acino 39
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 40
Norgine to Sell UK Rights for Somnite and Camcolit 41
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 42
Norgine Acquires Merus Labs International 44
Norgine BV, Key Competitors 46
Norgine BV, Key Employees 47
Norgine BV, Other Locations 48
Norgine BV, Subsidiaries 48
Norgine BV, Joint Venture 50

List Of Figures

List of Figures
Norgine BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Norgine BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Norgine BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Norgine BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Norgine BV, Medical Devices Deals, 2012 to YTD 2018 11

Norgine B.V. - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Norgine B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Norgine B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Norgine BV - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain

USD 250 View Report

Adyen BV - Strategy, SWOT and Corporate Finance Report

Adyen BV - Strategy, SWOT and Corporate Finance ReportAdyen BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the

USD 175 View Report

Daidalos Solutions BV - Product Pipeline Analysis, 2019 Update

Daidalos Solutions BV (Daidalos Solutions) is a medical device company. The company offers products such as sutureless biological heart valve prostheses, sutureless mechanical heart valve prostheses, sutureless heart valve repair

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available